Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-14
2007-08-14
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S009100, C514S011400, C530S328000, C530S329000, C530S317000
Reexamination Certificate
active
10369143
ABSTRACT:
The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition comprised of a somatostatin agonist to a patient suffering from insulin resistance or Syndrome X.
REFERENCES:
patent: 4133782 (1979-01-01), Vale, Jr. et al.
patent: 4146612 (1979-03-01), Veber
patent: 4190575 (1980-02-01), Sarantakis
patent: 4190648 (1980-02-01), Veber
patent: 4209426 (1980-06-01), Sarantakis
patent: 4211693 (1980-07-01), Rivier et al.
patent: 4215039 (1980-07-01), Sarantakis
patent: 4224199 (1980-09-01), Meyers et al.
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 4238481 (1980-12-01), Rink et al.
patent: 4261885 (1981-04-01), Sakakibara et al.
patent: 4282143 (1981-08-01), Sarantakis
patent: 4291022 (1981-09-01), Sandrin et al.
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 4316890 (1982-02-01), Kamber et al.
patent: 4328214 (1982-05-01), Rink et al.
patent: 4358439 (1982-11-01), Sieber et al.
patent: 4360516 (1982-11-01), Freidinger et al.
patent: 4369179 (1983-01-01), Rink et al.
patent: 4395403 (1983-07-01), Bauer et al.
patent: 4435385 (1984-03-01), Bauer et al.
patent: 4485101 (1984-11-01), Coy et al.
patent: 4486415 (1984-12-01), Freidinger
patent: 4522813 (1985-06-01), Nutt
patent: 4585755 (1986-04-01), Morgan et al.
patent: 4603120 (1986-07-01), Kamber
patent: 4650787 (1987-03-01), Schally et al.
patent: 4684620 (1987-08-01), Hruby et al.
patent: 4725577 (1988-02-01), Schally et al.
patent: 4728638 (1988-03-01), Bauer et al.
patent: 4853371 (1989-08-01), Coy et al.
patent: 4871717 (1989-10-01), Coy et al.
patent: 4904642 (1990-02-01), Coy et al.
patent: 5506339 (1996-04-01), Coy et al.
patent: 5583104 (1996-12-01), LaRusso
patent: 5686418 (1997-11-01), Culler
patent: 5708135 (1998-01-01), Coy et al.
patent: 5763200 (1998-06-01), Dunmore et al.
Van Bist et al., Peptide Research, vol. 5, No. 1, pp. 8-13, 1992.
Hosker et al., “Continuous infusion of glucose with model assesment: measurement of insulin resistance and Beta-cell function in man” 1985, Diabetologia, vol. 28, pp. 401-411.
Keith, et al., “u-Opioid Receptor Internalization: Opiate Drugs Have Differential Effects on a Conserved Endocytic Mechanism in vitro and in the Mammalian Brain,” Mol. Pharmacology, 1998, 53:377-384.
Lunec, J. et al., MSH Receptor Expression and the Relationship to Melanogenesis and Metastatic Activity in B16 Melanoma,: Melanoma Research, 1992, 2:5-12.
Mak, K-H. et al., “Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction,” JACC, 1997, 30(1):171-179.
Maruyama, Y. et al., “A Case of Insulin Dependent Diabetes Mellitus Following Systemic Treatment with Corticosteroids for Vogt-Koyanagi-Harada Syndrome,” Ophthalmic Surgery and Lasers, 2000, 31(6):487-490.
McFayden, I. J. et al., “Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2(Et): Effects on Opioid Receptor Binding and Activation,” J. Peptide Res., 2000, 55:255-261.
Nasushita, R. et al., “A Case of Acromegaly Accompanied by Adrenal Preclinical Cushing's Syndrome,” Endocrine Journal, 1999, 46(1):133-137.
O'Keefe, J. H. et al., “Improving the Adverse Cardiovascular Prognosis of Type 2 Diabetes,” Mayo Clin. Proc., 1999, 74:171-180.
Torsello, A. et al., “Short Ghrelin Peptides Neither Displace Ghrelin Binding in vitro nor Stimulate GH Release in vivo,” Endocrinology, 2002, 143(5):1968-1971.
Wandell, P. E. et al., “Drug Prescription in Diabetic Patients in Stockholm in 1992 and 1995—change over time,” Eur. J. Clin. Pharmacol., 1997, 52:249-254.
Warner, D. P. et al., “Mortality and Diabetes from a population based register in Yorkshire 1978-1993,” Arch. Dis. Child, 1998, 78:435-438.
Xiao, Q. et al., “Biological Activities of Glucagon-like Peptide-1 Analogues in vitro and in vivo,” Biochemistry, 2001, 40:2860-2869.
Zuanetti, G. et al., “Influence of Diabetes on Mortality in Acute Myocardial Infarction: Data from the GISSI-2 Study,” JACC, 1993, 22(7): 1788-1794.
Cawthorne Michael Anthony
Liu Yong-Ling
Sennitt Matthew V.
Ball Pamela C.
Feeney Alan F
Fish & Richardson
Mohamed Abdel A
Societe de Conseils de Recherches et d'Applications Scientifique
LandOfFree
Somatostatin and somatostatin agonists for treating insulin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Somatostatin and somatostatin agonists for treating insulin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin and somatostatin agonists for treating insulin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891995